Handelsbanken Fonder AB Buys 11,443 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Handelsbanken Fonder AB boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 4.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 267,186 shares of the medical equipment provider's stock after purchasing an additional 11,443 shares during the period. Intuitive Surgical makes up approximately 0.5% of Handelsbanken Fonder AB's portfolio, making the stock its 29th biggest holding. Handelsbanken Fonder AB owned approximately 0.08% of Intuitive Surgical worth $132,329,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Onefund LLC lifted its position in shares of Intuitive Surgical by 1.9% in the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after acquiring an additional 18 shares during the period. AlphaCore Capital LLC increased its position in shares of Intuitive Surgical by 4.2% during the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after purchasing an additional 18 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in Intuitive Surgical by 2.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock valued at $390,000 after purchasing an additional 19 shares during the last quarter. Accredited Investors Inc. boosted its position in Intuitive Surgical by 1.9% in the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after buying an additional 19 shares in the last quarter. Finally, Second Line Capital LLC increased its holdings in shares of Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after buying an additional 19 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 11,545 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $499.22, for a total value of $5,763,494.90. Following the transaction, the executive vice president now directly owns 5,224 shares of the company's stock, valued at $2,607,925.28. This represents a 68.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gary Loeb sold 1,700 shares of the company's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the completion of the transaction, the executive vice president now owns 2,245 shares in the company, valued at $1,152,089.10. This trade represents a 43.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,543 shares of company stock worth $8,375,072 over the last 90 days. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Down 1.1%

Shares of NASDAQ:ISRG traded down $5.75 during trading on Wednesday, hitting $523.85. 567,096 shares of the company were exchanged, compared to its average volume of 1,656,947. The stock has a market cap of $187.76 billion, a price-to-earnings ratio of 81.69, a P/E/G ratio of 5.85 and a beta of 1.67. Intuitive Surgical, Inc. has a fifty-two week low of $413.82 and a fifty-two week high of $616.00. The firm has a fifty day moving average price of $523.08 and a two-hundred day moving average price of $538.95.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same quarter last year, the company posted $1.50 earnings per share. As a group, research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Ratings Changes

ISRG has been the topic of several research analyst reports. Royal Bank of Canada decreased their target price on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Citigroup reissued a "buy" rating and set a $650.00 price target (up from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Truist Financial dropped their price objective on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Piper Sandler decreased their price objective on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Finally, BTIG Research set a $560.00 price objective on Intuitive Surgical and gave the stock a "buy" rating in a report on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $588.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.